Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Look for Opportunity in Walgreen Company (WAG)

Walgreen Company (NYSE:WAG), the largest drugstore retailer in the US, saw its biggest intraday fall (more than 7.5%) after it released its third quarter results. Though Walgreen Company (NYSE:WAG) gained 16% in revenues and 29% in adjusted earnings, it was caught short of the market expectations and also lost some ground on the same store sales. Walgreen, however, should not be looked down upon. It is a strategically solid stock, with a forward approach, and hence should be looked out for good opportunities.

Walgreen Company (NYSE:WAG)

Walgreen Company (NYSE:WAG), with more than 8,000 drugstores in the US, is engaged in retail sales of drugs, personal care products, supplements and other general merchandise like household goods, candies, etc. The company is based on the strategy of providing convenient access to healthcare services, which it provides through mail, telephone and the internet. It also operates Take Care Clinics, which, through more than 700 in-store clinics, provides medical treatment to patients including vaccinations.

Last year, in a cash-and-stock deal, Walgreen acquired a 45% stake in Alliance Boots, UK’s largest drugstore chain for $6.7 billion. The US and UK retailer, through the synergies offered by this deal prospect to pursue profitable growth and international expansion. Its forecasts include huge benefits from sharing best practices in store structuring, customer loyalty programs and e-commerce business. During May 2013, Alliance Boots released their annual results, posting an increase of 6% in annual earnings.

Numbers & financials

Walgreen Company (NYSE:WAG) posted third quarter revenues of $18.3 billion, an increase of 3.2%, driven mainly by prescription sales volume, offset by 3.9 % decrease in customer traffic in comparable stores. Gross Profit increased by 4.1% to $208 million, driven by increase in sales of high margin generic drugs, partially offset by increase in selling, general and administrative expenses by 5.3%.

Walgreen posted a GAAP-determined Net Earnings of $624 million (EPS of $0.65). However, non-GAAP adjusted net income for the quarter stood at $812 million (up by 29.3%), thereby computing an EPS of $0.85. The adjustments referred to one time legal settlement costs, negative impact of the LIFO provision and other one-time items linked to amortization, taxes and costs related to acquisition of Alliance Boots.

A 3% revenue growth is not exciting for a pharmaceutical company, which is a market leader. Moreover, there has been a drop in same store sales, which reflects that something went wrong.

What seems wrong?

Walgreen Company (NYSE:WAG) President and CEO Greg Wasson said, “Our front-end sales are still not up to our expectations, and while the economy remains challenging, increasing customer traffic and front-end sales are our near-term priorities with a focus on pricing and promotion and the leveraging of our Balance Rewards program, which now has 75 million members.”

It is evident that while attempting to get more on its plate, the company missed out on what’s falling off. Walgreen Company (NYSE:WAG) has its strategies right in place regarding the expansion, synergies and buying out smaller players. But, while getting them right, the company sidetracked the regular promotional activities much required to maintain a healthy growth in the comparable store sales and customer traffic.

The company needs to take action immediately to improve its front end sales and drive store traffic, by speeding up its promotional activities, leveraging on its loyalty programs, and increase in further sales of generic drugs. The company got an increase in its retail pharmacy market share by 80 basis points, and needs to grow this segment further.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.